Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Diagnostics and Epithelial-Mesenchymal Transition (EMT) Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Cytokeratin 19 / KRT19 drug discovery and diagnostic assay development. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KRT19 Full-Length / CYFRA 21-1 Cleaved Fragment (aa 244-400) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spec. Optimized for diagnostic calibrator development. |
View KRT19 Products |
| Gene Delivery | KRT19 Promise-ORF / Lentivirus Full-length human KRT19 ORF for stable cell line generation to study EMT and metastasis dynamics. |
View KRT19 Products |
| Benchmark Ab | Anti-KRT19 Recombinant Antibody (Sequence of BM19.21 / KS19.1 clones) Recombinant positive control for ELISA, IHC, and Western Blot validation. |
View KRT19 Products |
| Validator | KRT19 siRNA Set Validated siRNA pool for targeted knockdown verification in epithelial cancer cell lines. |
View KRT19 Products |
| Related Target A | KRT18 (Cytokeratin 18) Essential partner in intermediate filament networks; diagnostic counter-screening and co-expression analysis. |
View KRT18 Products |
| Related Target B | EPCAM (Epithelial Cell Adhesion Molecule) Classic epithelial tumor marker often co-monitored with KRT19 in circulating tumor cell (CTC) enrichment assays. |
View EPCAM Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High sequence homology across Cytokeratins leading to antibody cross-reactivity | KRT19 and related homolog panel proteins (KRT18, KRT8) strictly verified by mass spectrometry to guarantee sequence identity and purity. |
| Intermediate filament aggregation in physiological buffers during assay development | CYFRA 21-1 soluble fragment (aa 244-400) rationally designed and purified under optimized refolding conditions to prevent self-aggregation. |
| Lack of reliable calibration standards for clinical diagnostic development | Sequence-verified recombinant proteins with theoretical MW matching native cleaved fragments, ensuring predictable migration and antibody binding. |
| False positives in IHC/ELISA screening of novel diagnostic clones | Sequence-specific benchmark recombinant antibodies and validated siRNA knockdowns included for stringent specificity checks. |
Live Cytokeratin 19/KRT19 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The clinical utility of Cytokeratin 19 (KRT19) remains a cornerstone of oncology diagnostics, particularly through the detection of its soluble fragment, CYFRA 21-1, in non-small cell lung cancer (NSCLC), breast cancer, and bladder cancer. While traditionally utilized as a serum biomarker for treatment monitoring and recurrence detection, the target's role is expanding. Recent clinical research has positioned KRT19 as a crucial indicator of Epithelial-Mesenchymal Transition (EMT) and stemness in tumor cells, correlating directly with resistance to tyrosine kinase inhibitors (TKIs) and immune checkpoint therapies.
The race for KRT19-related therapeutics and diagnostics is diversifying, with major players shifting focus from traditional immunohistochemistry (IHC) mAbs to ultra-sensitive liquid biopsy assays and circulating tumor cell (CTC) detection platforms. As next-generation therapies targeting EMT pathways reach the clinic, the next wave of R&D is targeting KRT19 expression levels to stratify patients for combination therapies and to detect early resistance mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| In Vitro Diagnostics (IVD) / ELISA | Roche Diagnostics, Abbott, Siemens Healthineers | NSCLC (CYFRA 21-1), Bladder Cancer, Breast Cancer | Soluble, non-aggregating CYFRA 21-1 fragments for assay calibration and standard curve generation. |
| Liquid Biopsy / CTC Analysis | Menarini Silicon Biosystems, Guardant Health | Metastatic Breast Cancer, Colorectal Cancer | High-purity recombinant proteins for cross-reactivity screening against other cytokeratins (KRT18/KRT8). |
| EMT-Targeted Small Molecules | Academic Consortia, Biotech startups | Drug-Resistant Solid Tumors | Lentivirus-driven KRT19 overexpression models to validate downstream pathway inhibition and phenotypic reversal. |